Targeting signaling pathways in prostate cancer: mechanisms and clinical trials

Y He, W Xu, YT **ao, H Huang, D Gu… - Signal transduction and …, 2022‏ - nature.com
Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Current trends and challenges in cancer management and therapy using designer nanomaterials

PN Navya, A Kaphle, SP Srinivas, SK Bhargava… - Nano convergence, 2019‏ - Springer
Nanotechnology has the potential to circumvent several drawbacks of conventional
therapeutic formulations. In fact, significant strides have been made towards the application …

Polymersome-based protein drug delivery–quo vadis?

MG Gouveia, JP Wesseler, J Ramaekers… - Chemical Society …, 2023‏ - pubs.rsc.org
Protein-based therapeutics are an attractive alternative to established therapeutic
approaches and represent one of the fastest growing families of drugs. While many of these …

Current use of PSMA–PET in prostate cancer management

T Maurer, M Eiber, M Schwaiger… - Nature Reviews …, 2016‏ - nature.com
Currently, the findings of imaging procedures used for detection or staging of prostate
cancer depend on morphology of lymph nodes or bone metabolism and do not always meet …

Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology

N Bertrand, J Wu, X Xu, N Kamaly… - Advanced drug delivery …, 2014‏ - Elsevier
Cancer nanotherapeutics are progressing at a steady rate; research and development in the
field has experienced an exponential growth since early 2000's. The path to the …

The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

A Afshar-Oromieh, E Avtzi, FL Giesel… - European journal of …, 2015‏ - Springer
Purpose Since the introduction of positron emission tomography (PET) imaging with 68 Ga-
PSMA-HBED-CC (= 68 Ga-DKFZ-PSMA-11), this method has been regarded as a significant …

Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer

M Benešová, M Schäfer, U Bauder-Wüst… - Journal of Nuclear …, 2015‏ - jnm.snmjournals.org
Despite many advances in the past years, the treatment of metastatic prostate cancer still
remains challenging. In recent years, prostate-specific membrane antigen (PSMA) inhibitors …

68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies

M Weineisen, M Schottelius, J Simecek… - Journal of Nuclear …, 2015‏ - jnm.snmjournals.org
On the basis of the high and consistent expression of prostate-specific membrane antigen
(PSMA) in metastatic prostate cancer (PC), the goal of this study was the development …

Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

A Afshar-Oromieh, CM Zechmann, A Malcher… - European journal of …, 2014‏ - Springer
Purpose Positron emission tomography (PET) with choline tracers has found widespread
use for the diagnosis of prostate cancer (PC). However, choline metabolism is not increased …

Two decades of SPECT/CT–the coming of age of a technology: an updated review of literature evidence

O Israel, O Pellet, L Biassoni, D De Palma… - European journal of …, 2019‏ - Springer
Purpose Single-photon emission computed tomography (SPECT) combined with computed
tomography (CT) was introduced as a hybrid SPECT/CT imaging modality two decades ago …